Skip to main content

Table 1 Clinical characteristics of training (Moreno) and validation (TCGA) cohorts

From: A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence

Clinical Characteristic

Moreno Cohort (FFPE)

TCGA Cohort (RP)

Gleason Score

No. of patients (%)

No. of patients (%)

ā‰¤ 6 (3ā€‰+ā€‰3)

11 (11.00%)

37 (8.75%)

7 (3ā€‰+ā€‰4)

53 (53.00%)

162 (38.30%)

7 (4ā€‰+ā€‰3)

22 (22.00%)

101 (23.88%)

ā‰„ 8

14 (14.00%)

158 (37.35%)

Pathological Stage

ā€ƒpT2

69 (69.00%)

169 (39.95%)

ā€ƒpT3

2 (2.00%)

0 (0.00%)

ā€ƒpT3a

6 (6.00%)

138 (32.62%)

ā€ƒpT3b

9 (9.00%)

104 (24.59%)

ā€ƒpT4

1 (1.00%)

6 (1.42%)

Lymph Node Invasion

ā€ƒPresent

0 (0%)

60 (14.18%)

ā€ƒAbsent

37 (37.00%)

331 (78.25%)

Surgical Margins

ā€ƒPositive

39 (39.00%)

116 (27.42%)

ā€ƒNegative

56 (56.00%)

312 (73.76%)

Age

ā€ƒMedian

61.7

61

ā€ƒRange

43.0ā€“78.0

41.0ā€“77.0

Pre-operative PSA (ng/uL)

ā€ƒMedian

7.2

7.5

ā€ƒRange

1.8ā€“72.6

0.7ā€“107

Biochemical Recurrence

ā€ƒNumber of recurrences

49 (49.00%)

43 (10.17%)

ā€ƒAverage follow-up time in years (range)

5.79 (0.06ā€“15.26)

3.07 (0.06ā€“13.76)

Total

100

423